MX172602B - Composicion formada por microesferas y procedimiento mejorado para su preparacion - Google Patents

Composicion formada por microesferas y procedimiento mejorado para su preparacion

Info

Publication number
MX172602B
MX172602B MX024617A MX2461791A MX172602B MX 172602 B MX172602 B MX 172602B MX 024617 A MX024617 A MX 024617A MX 2461791 A MX2461791 A MX 2461791A MX 172602 B MX172602 B MX 172602B
Authority
MX
Mexico
Prior art keywords
mixture
microspheres
preparation
composition formed
improved procedure
Prior art date
Application number
MX024617A
Other languages
English (en)
Inventor
William Steber
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of MX172602B publication Critical patent/MX172602B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

La presente invención se refiere a un procedimiento mejorado para preparar una composición de microesferas que tiene las etapas de mezclado en estado fundido de una grasa o cera o una mezcla de ellas y una proteína, peptido o polipeptido biológicamente activo para formar una mezcla y convertir en aglomerados esfericos la mezcla para formar la composición de microesferas, la cual mejora consiste en mezclar aproximadamente del 1 al 30 por ciento de un aceite, grasa semi-suave, derivado de ácido graso o mezcla de ellos antes de convertir en aglomerados esfericos la mezcla.
MX024617A 1990-03-30 1991-02-20 Composicion formada por microesferas y procedimiento mejorado para su preparacion MX172602B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/502,382 US5213810A (en) 1990-03-30 1990-03-30 Stable compositions for parenteral administration and method of making same

Publications (1)

Publication Number Publication Date
MX172602B true MX172602B (es) 1993-01-03

Family

ID=23997559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX024617A MX172602B (es) 1990-03-30 1991-02-20 Composicion formada por microesferas y procedimiento mejorado para su preparacion

Country Status (29)

Country Link
US (1) US5213810A (es)
EP (1) EP0448930B1 (es)
JP (1) JP2966564B2 (es)
KR (1) KR0159778B1 (es)
CN (1) CN1063941C (es)
AR (1) AR248085A1 (es)
AT (1) ATE106240T1 (es)
AU (1) AU641994B2 (es)
BG (1) BG60850B1 (es)
CA (1) CA2039491C (es)
CZ (1) CZ283053B6 (es)
DE (1) DE69102176T2 (es)
DK (1) DK0448930T3 (es)
ES (1) ES2054380T3 (es)
FI (1) FI101676B (es)
HK (1) HK1000004A1 (es)
HU (1) HU219584B (es)
IE (1) IE65970B1 (es)
IL (1) IL97145A (es)
MX (1) MX172602B (es)
NO (1) NO300717B1 (es)
NZ (1) NZ237509A (es)
PL (1) PL167692B1 (es)
PT (1) PT97160B (es)
RO (1) RO106191B1 (es)
RU (1) RU2011377C1 (es)
SK (1) SK279461B6 (es)
YU (1) YU47650B (es)
ZA (1) ZA912398B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134873T1 (de) * 1991-07-23 1996-03-15 American Cyanamid Co Stabile zusammensetzungen für parenterale verabrechung und ihre verwendung
WO1994017106A1 (en) * 1993-01-19 1994-08-04 Pharmacia P-L Biochemicals, Inc. Storage and delivery of purified protein reagents with carrier wax
US5599660A (en) * 1993-01-19 1997-02-04 Pharmacia Biotech Inc. Method and preparation for sequential delivery of wax-embedded, inactivated biological and chemical reagents
US6083430A (en) * 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
AU2002300572B2 (en) * 1997-09-19 2004-11-25 Shire Laboratories, Inc. Solid Solution Beadlet
AU9496798A (en) 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
CA2369594A1 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
CA2376202C (en) * 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
US6544646B2 (en) 2000-04-27 2003-04-08 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
WO2002000028A1 (en) * 2000-06-26 2002-01-03 Martek Biosciences Boulder Corporation Improved methods of incorporating polyunsaturated fatty acids in milk
WO2002026372A2 (en) 2000-09-27 2002-04-04 Verion Inc. Instant water dissolvable encapsulate and process
ATE392887T1 (de) * 2000-10-10 2008-05-15 Wyeth Corp Stabilisierte arzneizusammensetzungen zur parenteralen vearbreichung
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
RU2006119453A (ru) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053655A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547773A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8221809B2 (en) * 2006-06-22 2012-07-17 Martek Biosciences Corporation Encapsulated labile compound compositions and methods of making the same
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
JP5494957B2 (ja) 2009-06-11 2014-05-21 株式会社リコー 静電荷像現像用トナー、現像剤、画像形成方法及び画像形成装置
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9364549B2 (en) * 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
EP3003266A2 (en) * 2013-05-29 2016-04-13 Therakine Biodelivery GmbH Hydrophilic microparticles, drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス,インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
EP3927715A4 (en) * 2019-02-21 2023-03-01 Chromadex, Inc. USE OF NICOTINAMIDE RIBOSIDE, NICOTINOIC ACID RIBOSIDE, REDUCED NICOTINYL RIBOSIDE COMPOUNDS AND NICOTINYL RIBOSIDE COMPOUNDS IN FORMULATIONS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
DE3024416C2 (de) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4666839A (en) * 1982-12-01 1987-05-19 Amgen Methods and materials for obtaining microbial expression of polypeptides including bovine prolactin
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4755387A (en) * 1985-03-21 1988-07-05 The Procter & Gamble Company Therapeutic particles
DE3527356A1 (de) * 1985-07-31 1987-02-05 Degussa Verfahren zur verbesserung der fruchtbarkeit von haustieren
SE462894B (sv) * 1985-10-28 1990-09-17 Biogram Ab Mikrokapslar, foerfarande foer framstaellning daerav samt anvaendning
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles

Also Published As

Publication number Publication date
AU641994B2 (en) 1993-10-07
YU47650B (sh) 1995-12-04
KR0159778B1 (ko) 1998-12-01
PL167692B1 (en) 1995-10-31
PT97160B (pt) 1998-07-31
DE69102176T2 (de) 1995-01-05
AU7397291A (en) 1991-10-03
HK1000004A1 (en) 1997-10-03
EP0448930A1 (en) 1991-10-02
FI101676B1 (fi) 1998-08-14
CN1063941C (zh) 2001-04-04
IL97145A (en) 1996-06-18
YU57091A (sh) 1994-01-20
US5213810A (en) 1993-05-25
KR910016322A (ko) 1991-11-05
HU219584B (hu) 2001-05-28
JP2966564B2 (ja) 1999-10-25
CA2039491A1 (en) 1991-10-01
BG60850B1 (bg) 1996-05-31
NO911228D0 (no) 1991-03-26
PL289657A1 (en) 1992-01-13
DK0448930T3 (da) 1994-06-20
IE65970B1 (en) 1995-11-29
DE69102176D1 (de) 1994-07-07
ES2054380T3 (es) 1994-08-01
FI911531A0 (fi) 1991-03-28
IE911041A1 (en) 1991-10-09
CN1055293A (zh) 1991-10-16
NZ237509A (en) 1993-04-28
ZA912398B (en) 1992-01-29
FI911531A (fi) 1991-10-01
JPH04221319A (ja) 1992-08-11
PT97160A (pt) 1991-11-29
ATE106240T1 (de) 1994-06-15
SK279461B6 (sk) 1998-11-04
FI101676B (fi) 1998-08-14
EP0448930B1 (en) 1994-06-01
RO106191B1 (ro) 1993-03-31
CZ283053B6 (cs) 1997-12-17
HU911054D0 (en) 1991-10-28
IL97145A0 (en) 1992-05-25
RU2011377C1 (ru) 1994-04-30
NO911228L (no) 1991-10-01
NO300717B1 (no) 1997-07-14
AR248085A1 (es) 1995-06-30
CA2039491C (en) 2001-09-04
HUT59834A (en) 1992-07-28

Similar Documents

Publication Publication Date Title
MX172602B (es) Composicion formada por microesferas y procedimiento mejorado para su preparacion
UY23705A1 (es) Microesferas de proteina vegetal hidrolizada y metodos para la preparacion y uso de las mismas.
DE69934627D1 (de) Konjugierte Linolsäurezusammensetzung
WO2003000014A3 (en) Spherical protein particles and methods of making and using them
BR9808933A (pt) Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo
ES2068999T3 (es) Composiciones para la liberacion retardada de clorhexidina.
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
FR2442054A1 (fr) Proteines purifiees, notamment interferon, procede de preparation et compositions pharmaceutiques les contenant
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
DK74187A (da) Praeparat til langsom frigivelse samt fremgangsmaade til fremstilling deraf
BR9916053B1 (pt) composições contendo um peptìdeo e um ácido glicólico poliláctico, adequadas para preparação de implantes subcutáneos com perìodo de liberação prolongado.
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
AR059120A2 (es) Sal de dicarboxilato del (1s,4r) -4- (2-amino-6- (ciclopropilamino ) -9h- purin-9-il)-2- ciclopenten -1- metanol y procedimiento para su preparacion
HU223421B1 (hu) Kazein-glikomakropeptidet tartalmazó,stabilan tárolható fogápoló készítmény
BR0008255A (pt) Composição e processo para formar emulsão estável sob cisalhamento
PT1014947E (pt) Metodo de preparacao de composicoes farmaceuticas de particulas lipidicas compreendendo um agente lipidico e uma proteina
AR019000A1 (es) Emulsion y proceso para produccion; gel y proceso para su produccion; ingrediente funcional de alimentos que los comprenden; alimento, bebida y cosmetico que comprenden dicha emulsion
IL152406A0 (en) Anti-freeze proteins, their production and use
ES2185367T3 (es) Hidrogeles poliionicos a base de xantano y qutosan para la estabilizacion y la separacion contr0ladas de las vitaminas.
KR890008171A (ko) 펩타이드 구조물, 이를 함유하는 면역원 및 수정율 억제에 있어서 이의 용도
DE60323356D1 (de) Zusammensetzungen enthaltend protein und fettsäure und verfahren zur herstellung
JP4142057B2 (ja) 美容用送達システムおよびこの製造のための方法
Kessel et al. Unusual particle arrays in the plasma membrane of zebrafish spermatozoa
DE69025378T2 (de) Implantatmaterialzusammensetzung, ihre Herstellung sowie ihre Verwendungen und daraus erhältliches Implantat
ATE228556T1 (de) An omega-3 ungesättigten fettsäuren angereicherte wachsester, ihre herstellung und verwendung